Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of efficient perindopril tablet and its production process

An indopril tablet and production process technology, applied in the field of high-efficiency perindopril tablet and its production process, can solve problems such as loss of taste, less adverse reactions, nephrotoxicity, etc., achieve blood pressure control, prevent occurrence and The effect of developing and improving heart function

Active Publication Date: 2016-03-30
SHANGHAI PHARMA DONGYING JIANGSU PHARMA CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The first-generation ACEI has disadvantages such as loss of taste and nephrotoxicity, so it is necessary to find compounds with peripheral properties and few adverse reactions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of efficient perindopril tablet and its production process
  • A kind of efficient perindopril tablet and its production process
  • A kind of efficient perindopril tablet and its production process

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] A high-efficiency perindopril tablet comprises the following components:

[0027]

[0028] Finally, a tablet with a total tablet weight of 70-80 mg is obtained, and its preparation process comprises the following steps:

[0029] (1) Perindopril tert-butylamine salt is successively mixed with sodium starch glycolate, lactose, and magnesium oxide in equal amounts;

[0030] (2) above-mentioned mixture is mixed with microcrystalline cellulose;

[0031] (3) Add an appropriate amount of binder to make soft materials, and dry and granulate at 70°C;

[0032] (4) Add additional auxiliary materials and mix for 45 minutes;

[0033] (5) Sampling and testing the content and content uniformity of intermediate products, ∮6mm punch for tableting, aluminum-plastic packaging.

Embodiment 2

[0035] A high-efficiency perindopril tablet comprises the following components:

[0036]

[0037] Finally, a tablet with a total tablet weight of 70-80 mg is obtained, and its preparation process comprises the following steps:

[0038] (1) Perindopril tert-butylamine salt is successively mixed with sodium starch glycolate, lactose, and magnesium oxide in equal amounts;

[0039] (2) above-mentioned mixture is mixed with microcrystalline cellulose;

[0040] (3) Add an appropriate amount of adhesive to make soft materials, and carry out drying and sizing at 50°C;

[0041] (4) Add additional auxiliary materials and mix for 15 minutes;

[0042] (5) Sampling and testing the content and content uniformity of intermediate products, ∮6mm punch for tableting, aluminum-plastic packaging.

Embodiment 3

[0044] A high-efficiency perindopril tablet comprises the following components:

[0045]

[0046]

[0047] Finally, a tablet with a total tablet weight of 70-80 mg is obtained, and its preparation process comprises the following steps:

[0048] (1) Perindopril tert-butylamine salt is successively mixed with sodium starch glycolate, lactose, and magnesium oxide in equal amounts;

[0049] (2) above-mentioned mixture is mixed with microcrystalline cellulose;

[0050] (3) Add an appropriate amount of adhesive to make soft materials, and dry and granulate at 60°C;

[0051] (4) Add additional auxiliary materials and mix for 30 minutes;

[0052] (5) Sampling and testing the content and content uniformity of intermediate products, ∮6mm punch for tableting, aluminum-plastic packaging.

[0053] Below in conjunction with specific clinical use the present invention will be further described:

[0054] 1.1 Case selection

[0055]Randomly select 60 patients who meet the 1999 WHO / I...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an efficient perindopril tablet and a production process thereof. The tablet consists of the following components: perindopril tert-butylamine, microcrystalline cellulose, lactose, sodium carboxy methyl starch, pregelatinized starch, magnesium oxide, magnesium stearate and appropriate adhesives. The perindopril tablet is prepared by adopting a method in which internal addition and external addition are carried out separately. The invention provides an efficient and convenient treatment medicine for patients with hypertension and has an important significance in controlling blood pressure of patients, preventing generation and development of cardiovascular diseases of patents, controlling generation of renal lesions of hypertension patients accompanying with diabetes, improving the cardiac function of patients and reducing the occurrence ratio of serious incidents of myocardial infarction and the like.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical manufacturing, and in particular relates to a high-efficiency perindopril tablet and a production process thereof. Background technique [0002] Angiotensin-converting enzyme inhibitors (Angiotensin Converting Enzyme Inhibitors, ACEI) is a new class of antihypertensive drugs and anti-congestive heart failure drugs developed in the 1980s. Since 1970, Brazilian scientists have isolated a variety of substances that can inhibit angiotensin-converting enzyme (Angiotensin Converting Enzyme, ACE) from snake venom. In combination with the thiol substitution, the first ACEI marketed named captopril was developed. The first-generation ACEI has disadvantages such as loss of taste and nephrotoxicity, so it is necessary to find compounds with peripheral properties and few adverse reactions. In 1976, Japanese pharmacists screened out the second-generation ACEI enalapril from the phthalazine series indu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/05A61K9/20A61P9/12A61P9/00A61P9/10A61P13/12
Inventor 陈丽姜允菊张秋姜丽华
Owner SHANGHAI PHARMA DONGYING JIANGSU PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com